ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.

导出 OA

翻译打印收藏纠错

作者： Enrique M,Ocio ^[1] ; Yvonne A,Efebera ^[2] ; Roman,Hájek ^[3] ; Jan,Straub ^[4] ; Vladimir,Maisnar ^[5] ; Jean-Richard,Eveillard ^[6] ; Lionel,Karlin ^[7] ; María-Victoria,Mateos ^[8] ; Albert,Oriol ^[9] ; Vincent,Ribrag ^[10] ; Paul G,Richardson ^[11] ; Stefan,Norin ^[12] ; Jakob,Obermüller ^[12] ; Nicolaas A,Bakker ^[12] ; Luděk,Pour ^[13]

作者单位： Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander. ocioem@unican.es. ^[1] Department of Hematology/Oncology, Division of Blood and Marrow Transplant and Cellular Therapy, OhioHealth, Columbus, OH, USA and OhioHealth, Columbus, OH. ^[2] Department of Hematooncology, University Hospital Ostrava, Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. ^[3] Všeobecná fakultní nemocnice, Prague, Czech Republic. ^[4] Fourth Department of Medicine - Hematology, Charles University Hospital, Hradec Králové, Czech Republic. ^[5] Hôpital Morvan, Brest. ^[6] Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre-Bénite. ^[7] Hospital Clinico Universitario de Salamanca/IBSAL/CIC, Salamanca. ^[8] Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona. ^[9] Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif. ^[10] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. ^[11] Oncopeptides AB, Stockholm. ^[12] Fakultní nemocnice Brno, Brno, Czech Republic. ^[13]